Alzinova AB

ALZ

SE0007413455

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 15/07/2026 BST			5-day change	1st Jan Change
0.7210 ^SEK	-6.49%		-48.50%	-13.03%

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT

Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today

Published on 04/27/2026 at 10:24 am BST

Finwire - Translated by Marketscreener - See original

Add MarketScreener to your sources

-6.49%

+1.57%

-1.09%

+0.49%

WASTE MANAGEMENT, INC.

-0.63%

As of mid-morning trading, seven new 52-week lows have been recorded across the Stockholm Stock Exchange listings.

The data was compiled at approximately 11:20 AM.

Stock	New 52-week low	Previous 52-week low	Previous date

Alzinova	0.44	0.45	2026-04-24
Diamyd Medical B	0.971	0.974	2026-04-24
Elicera Therapeutics	3.11	3.20	2026-04-24
Knowit	96.50	97.30	2026-04-24
Nederman Holding	118.00	118.60	2026-04-24
Netel	3.60	3.65	2026-04-24
SCA B	103.30	104.30	2026-04-24

Source: FactSet

Add MarketScreener to your sources

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
ALZINOVA AB	0.7210SEK	-6.49%	-48.50%	12.4M
KNOWIT AB	84.00SEK	+1.57%	-0.24%	234M
DIAMYD MEDICAL AB	1.086SEK	-1.09%	-3.04%	17.66M
NETEL HOLDING AB	3.100SEK	+0.49%	-7.74%	15.53M
WASTE MANAGEMENT, INC.	232.80USD	-0.63%	-1.86%	94.08B

Latest news about Alzinova AB

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company